Allegro Inks Second Asian Alliance For Luminate

Allegro has secured a second Asian partner for its novel integrin peptide therapy for ophthalmic disorders, linking with Hanmi for the Korean and Chinese markets.

Seoul-based Hanmi Pharmaceutical Co. Ltd. will pay an undisclosed upfront fee and sales milestones, plus running percentage royalties on net sales, in return for development and marketing rights in South Korea and mainland China to Allegro Ophthalmics LLC's Luminate (ALG-1001).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia